Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01609556 (Clinical Trial / IMGN853 / mirvetuximab soravtansine)

Study Title
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors (IMGN-0401) (NCT01609556)

Trial Description
The purpose of this study is to test IMGN853 (also known as mirvetuximab soravtansine) in patients with FOLR-1 positive tumors.

This trial is sponsored by ImmunoGen, Inc. [1]

Study Data

  • Condition: FOLR-1 Positive Solid Tumors
  • Interventions:
    • Drugs used in this trial
      • IMGN853 (mirvetuximab soravtansine)
  • Phase: I
  • Estimated Enrollment: 205
  • Start: May 2012
  • Estimated Completion: September 2016
  • Last verified: June 2015

Study Schematic 

NCT01609556


Last Editorial review: November 2, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar